188 related articles for article (PubMed ID: 38188537)
21. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
[TBL] [Abstract][Full Text] [Related]
22. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
23. Deucravacitinib for the Treatment of Psoriatic Disease.
Lé AM; Puig L; Torres T
Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487
[TBL] [Abstract][Full Text] [Related]
24. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
Martin G
Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
[TBL] [Abstract][Full Text] [Related]
25. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
Armstrong AW; Park SH; Patel V; Nicolas P; Wang WJ; Colombo MJ; Chirikov V
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38907877
[TBL] [Abstract][Full Text] [Related]
26. Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
Armstrong AW; Warren RB; Zhong Y; Zhuo J; Cichewicz A; Kadambi A; Junqueira D; Westley T; Kisa R; Daamen C; Augustin M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2839-2857. PubMed ID: 37801281
[TBL] [Abstract][Full Text] [Related]
27. Deucravacitinib: First Approval.
Hoy SM
Drugs; 2022 Nov; 82(17):1671-1679. PubMed ID: 36401743
[TBL] [Abstract][Full Text] [Related]
28. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A; Rich P; Sofen H; Strober B; Merola JF; Lebwohl M; Morita A; Szepietowski JC; Lambert J; Hippeli L; Colston E; Balagula E; Banerjee S; Thaçi D
J Am Acad Dermatol; 2024 Apr; 90(4):775-782. PubMed ID: 38122848
[TBL] [Abstract][Full Text] [Related]
29. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
31. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.
Jing S; Lin Y; Dockens R; Marchisin D; He B; Girgis IG; Chimalakonda A; Murthy B; Aras U
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3153-3164. PubMed ID: 37981596
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation.
Potestio L; Tommasino N; Lauletta G; Feo F; Ruggiero A; Martora F; Portarapillo A; Guerriero L; Megna M
Expert Opin Drug Saf; 2024 Jun; 23(6):677-685. PubMed ID: 38699874
[TBL] [Abstract][Full Text] [Related]
34. SOTYKTU
Gupta AK; Wang T; Vincent K; Abramovits W
Skinmed; 2023; 21(3):192-196. PubMed ID: 37634105
[TBL] [Abstract][Full Text] [Related]
35. Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults.
Dos Santos RS; Guzman-Llorens D; Perez-Serna AA; Nadal A; Marroqui L
Front Immunol; 2023; 14():1263926. PubMed ID: 37854597
[TBL] [Abstract][Full Text] [Related]
36. TYK2 as a novel therapeutic target in psoriasis.
Elyoussfi S; Rane SS; Eyre S; Warren RB
Expert Rev Clin Pharmacol; 2023; 16(6):549-558. PubMed ID: 37287330
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Mease PJ; Deodhar AA; van der Heijde D; Behrens F; Kivitz AJ; Neal J; Kim J; Singhal S; Nowak M; Banerjee S
Ann Rheum Dis; 2022 Jun; 81(6):815-822. PubMed ID: 35241426
[TBL] [Abstract][Full Text] [Related]
38. Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States.
Park SH; Lambton M; Schmier J; Hovland S; Wittstock K; Patel V
J Dermatolog Treat; 2024 Dec; 35(1):2366503. PubMed ID: 38914425
[TBL] [Abstract][Full Text] [Related]
39. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
40. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
Zhang L; Guo L; Wang L; Jiang X
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]